mazdutide

Innovent gets seven drugs on China's 2026 NRDL, four new

SUZHOU -- November 14, 2026 -- Innovent Biologics (HKEX: 01801) had seven products included or renewed in China's updated National Reimbursement Drug List (NRDL), four of them first-time listings. The list takes effect on January 1, 2027. CEO Michael Yu says the company's NRDL-covered lineup has expanded to 17 products that have cumulatively benefited more than 20 million patients. By our calculation, the seven decisions in this round touch about 41% of that lineup (7 of 17).

Four Innovent products enter the NRDL for the first time

The new entries are mazdutide, PECONDLE (picankibart), TABOSUN (ipilimumab N01) and VANFLYTA (quizartinib). The other three were already listed. TYVYT (sintilimab) and JAYPIRCA (pirtobrutinib) gained indications, and SINTBILO (tafolecimab) was renewed.